Last year, just a few weeks before the Janssen deal, I suggested HALO partner with Celltrion for their Remicade biosimilar. (My timing was lucky) Not that Celltrion is far enough along in any development, but I still think it would be a good idea to find some way to partner with them on something. They clearly are the leader now in biosimilar aspirations and a working relationship with them might serve notice to big pharma they need to take their deals with. Halozyme seriously.
News 
Market Data 
Discover 
